10-Q: Inspire Veterinary Partners Faces Nasdaq Delisting Risk

Inspire Veterinary Partners reports a reduced net loss and improved clinic EBITDA for Q2 2025, but faces substantial doubt about its going concern status and Nasdaq listing compliance.

Summary

• Net loss for the six months ended June 30, 2025, decreased by 22% to $5,449,604, compared to $6,808,213 for the same period in 2024.
• Total revenue for the six months ended June 30, 2025, declined by 14% to $7,922,743, from $9,221,948 in the prior year, primarily due to the divestiture of Kauai Veterinary Clinic (KVC) in Q3 2024.
• Service revenue decreased by 12% and product revenue by 19% for the six months ended June 30, 2025, compared to the same period in 2024.
• Adjusted Clinics EBITDA significantly improved to $286,646 for the six months ended June 30, 2025, up from $162,976 in the prior year.
• The company acquired DeBary Animal Clinic on June 4, 2025, for approximately $1,942,500, consisting of $1,850,000 cash and $92,500 in Class A common stock.
• As of June 30, 2025, the company had an accumulated deficit of $41,799,885 and negative working capital of $8,717,747.
• The company received a Nasdaq notice on April 10, 2025, for non-compliance with the minimum stockholders' equity requirement, which stood at $1,562,005 as of December 31, 2024.
• A 25-for-1 reverse stock split was effected on January 27, 2025.
• Subsequent to the reporting period, the company completed the first closing of a private placement of Series B convertible preferred stock and warrants, raising approximately $5 million out of a target of up to $10 million.
• Also, subsequent to the reporting period, the company entered into a Common Stock Purchase Agreement for up to $50 million in shares from an accredited investor.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by a 'going concern' warning, significant accumulated deficit, negative working capital, and Nasdaq non-compliance. While net loss decreased and Adjusted Clinics EBITDA improved, the overall revenue decline and reliance on high-interest debt and continuous capital raises indicate a highly precarious situation. The subsequent capital raises are critical but do not eliminate the fundamental financial instability.

Positives

• Net loss decreased by 22% for the six months ended June 30, 2025, indicating an improvement in overall profitability compared to the prior year.
• Adjusted Clinics EBITDA increased significantly to $286,646 for the six months ended June 30, 2025, up from $162,976, suggesting improved operational efficiency at the clinic level.
• Cash used in operating activities decreased to $2,272,581 for the six months ended June 30, 2025, from $3,019,312 in the prior year, indicating more efficient cash management in core operations.
• Successful acquisition of DeBary Animal Clinic in June 2025 expands the company's network to 14 clinics across 9 states.
• Subsequent capital raising activities, including a $5 million private placement and a $50 million common stock purchase agreement, demonstrate active efforts to address liquidity and fund future growth.

Negatives

• Total revenue decreased by 14% for the six months ended June 30, 2025, primarily due to the divestiture of Kauai Veterinary Clinic, but also reflecting a general decline in service and product revenue per clinic.
• The company has an accumulated deficit of $41,799,885 and negative working capital of $8,717,747 as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq notice for non-compliance with the minimum stockholders' equity requirement, indicating a risk of delisting.
• High effective interest rates on merchant cash advance agreements (e.g., 42% on the May 2025 amendment) continue to burden the company with significant interest expense and debt extinguishment losses.
• Cash and cash equivalents significantly decreased to $158,942 as of June 30, 2025, from $523,690 at December 31, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, accumulated deficit, and negative working capital.
• Non-compliance with Nasdaq's minimum stockholders' equity requirement poses a risk of delisting, which could negatively impact stock liquidity and investor confidence.
• The company's continuation as a going concern is contingent upon its ability to obtain additional financing and generate sufficient revenue and cash flow, with no guarantee of success.
• Future funding may not be available on acceptable terms or at all, and equity offerings could dilute existing stockholders while debt financing may impose restrictive covenants.
• High interest rates on existing and future debt, particularly merchant cash advances, could negatively impact profitability and valuation of acquired hospitals.
• Acquisition and integration risks include national staffing shortages of veterinarians and technicians, costs and time associated with due diligence, and difficulties in achieving post-purchase growth targets.
• Post-purchase pressures include rising talent acquisition and staffing costs, and challenges in achieving productivity and average patient charges necessary for growth and profitability.

Future Outlook

The company intends to continue its growth strategy by strategically acquiring existing general practice, specialty hospitals, and/or expanding existing locations to include emergency care and more complex surgeries, holistic care, and comprehensive diagnostics. It also plans to seek multi-unit practices with regional presence to accelerate growth and provide internal benefits like case referrals and career pathing. The company will continue to seek additional funding through debt or equity financing over the next twelve months to support its operations and growth initiatives.

Management Comments

• Management believes that actions presently being taken to obtain additional funding provide the opportunity for the company to continue as a going concern.
• The company's objective is to protect the service channel and derive the majority of its revenue from services and expertise which are not capable of disruption from other channels, aiming for 70% to 80% of gross revenue from services.
• The company views products such as parasite controls, veterinary nutrition products and additives as important, but does not rely on product revenue to account for more than 20% to 30% of gross revenue.
• Management uses metrics like Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) to analyze the comprehensive nature of diagnostics and services provided by each veterinary hospital, ensuring caseload is revenue positive and clinicians' time is utilized effectively.

Industry Context

The company operates in the U.S. veterinary services industry, specializing in small animal general practice, with recent expansion into equine care and plans for emergency and mixed animal services. The industry faces challenges such as national staffing shortages of veterinarians and technicians, which can make finding credentialed talent difficult and increase talent acquisition costs. The company's strategy of acquiring existing hospitals and leveraging a distributed support structure allows for broad geographic expansion, aiming to consolidate a fragmented market. Its focus on service revenue (70-80% target) aligns with industry best practices to mitigate disruption from over-the-counter or online product sales.

Comparison to Industry Standards

• The company's target of 70% to 80% of gross revenue derived from services (examination fees, diagnostics, surgery) aligns with generally accepted industry targets for veterinary care providers, aiming to protect against disruption from non-veterinary channels.
• The company utilizes metrics such as Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) to analyze the comprehensive nature of diagnostics and services, which are considered 'quality medicine metrics' within the veterinary service industry.
• The company's valuation approach for client lists uses a Veterinary Services industry retention rate of 74.0%, which is a specific benchmark for customer base stability in the sector.
• While specific comparable companies are not named for direct financial comparison, the company's acquisition strategy and operational focus on service-to-product revenue mix are common in the consolidating veterinary practice market, similar to larger players like VCA Animal Hospitals (Mars Petcare) or Banfield Pet Hospital (Mars Petcare), though on a much smaller scale and with different financial profiles.

Corporate Governance

Related Party Transactions

• The company incurred $59,043 in expenses for Blue Heron Consulting (BHC) for the six months ended June 30, 2025. Charles Stith Keiser, a company director, is the COO of BHC, and his father, Dr. Charles Chuck Keiser, is the CVO of BHC.
• The divestiture of Kauai Veterinary Clinic (KVC) on September 20, 2024, was to Kauai RE Holdings LLC, where Gregory Armstrong (a current shareholder) and Charles Keiser (father of board member Charles Stith Keiser, the largest shareholder) are members.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and planned equity capital raises, potential loss of investment due to 'going concern' doubt, and risk of delisting from Nasdaq.
• **Employees**: Continued employment for former owners of acquired clinics is tied to holdback payments, indicating a focus on retention and performance incentives.
• **Customers**: The company's focus on maintaining a high percentage of service revenue (70-80%) aims to ensure comprehensive medical care and reduce susceptibility to competition from non-veterinary channels, potentially benefiting pet owners through quality care.
• **Creditors**: The company's substantial debt, high interest rates on certain loans, and 'going concern' warning indicate elevated risk for creditors, although the company states it is in compliance with all covenants as of the filing date.
• **Suppliers**: No specific impact mentioned, but general financial instability could pose risks to supplier relationships if payment terms are affected.

Next Steps

• Nasdaq is reviewing the company's plan to regain compliance with the minimum stockholders' equity requirement.
• The company will continue to seek additional funding through debt or equity financing during the next twelve months.
• The remaining $120,000 holdback amount for the Valley Vet acquisition is contingent upon former owners' continued employment and revenue targets as of November 8, 2025.
• The $114,500 holdback amount for the DeBary Animal Clinic acquisition is contingent upon former owner's continued employment and revenue targets as of June 3, 2026, and June 3, 2027.
• The company entered a non-binding Letter of Intent (LOI) on August 7, 2025, to purchase another animal hospital and clinic.
• The company plans to file a registration statement with the SEC to register the resale of common stock issuable upon conversion of Series B Preferred Stock and exercise of Warrants from the July 28, 2025 private placement.

Key Dates

Recommendation

The company is in a highly precarious financial state, evidenced by a 'going concern' warning, substantial accumulated deficit, negative working capital, and a Nasdaq non-compliance notice that could lead to delisting. While management is actively pursuing capital raises and acquisitions, the high effective interest rates on existing debt and the overall revenue decline (despite KVC divestiture) indicate significant underlying challenges. The risk of further dilution for existing shareholders and the uncertainty surrounding the company's long-term viability make it a high-risk investment. A seasoned investor would likely view the fundamental financial instability and delisting risk as outweighing the operational improvements in Adjusted Clinics EBITDA and the efforts to raise capital, suggesting an exit position.

Keywords

Veterinary Services, Animal Hospitals, SEC Filing, 10-Q, Financial Results, Acquisitions, Nasdaq Compliance, Going Concern, Capital Raise, Debt Financing, Veterinary Clinics, Pet Care